Nxera Pharma's Partner Neurocrine Biosciences Doses First Patient In Phase 2 Trial Of Nbi-1117570 For Adults With Schizophrenia
13/04/2026 24:32
April 13 (Reuters) - Nxera Pharma Co Ltd 4565.T: NXERA PHARMA CO LTD - NXERA PHARMA'S PARTNER NEUROCRINE BIOSCIENCES DOSES FIRST PATIENT IN PHASE 2 TRIAL OF NBI-1117570 FOR ADULTS WITH SCHIZOPHRENIA Source text: ID:nTSpl7a993 Further company coverage: 4565.T
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up